Clinical trials: Myeloma, Multiple
Multiple Myeloma
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in…
- Trial name
- MOCCCA (NCT03442673)
- Testing
- Vinorelbine, Gemcitabine, G-CSF
- Where
- Switzerland
- Volunteers
- 137 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to…
- Trial name
- Z-MARK (NCT00622505)
- Testing
- zoledronic acid
- Where
- 42 sites in United States
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Relapse/Refractory Multiple Myeloma
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
- Trial name
- NCT06084962
- Testing
- DeepTag-GPRC5D Targeted CAR T-cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- He Huang
Multiple Myeloma
Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans
The overarching objective of this study is to evaluate the symptom assessment and management behaviors used by multiple myeloma (MM) providers for alignment with evidence-based practices, and to explore changes in these symptom…
- Trial name
- NCT03046329
- Testing
- Carevive CPS
- Volunteers
- 90 people
- Sponsor
- Carevive Systems, Inc.
Myeloma Multiple
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive
Aim of this study is to evaluate Daratumumab effect on MRD-positive patients with Multiple Myeloma (MM) who achieved >VGPR after any therapy (ASCT, VMP, Rev-Dex).
- Trial name
- DART4MM (NCT03992170)
- Testing
- Daratumumab
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Multiple Myeloma
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
This research is being done to find out if the investigators can improve outcomes for multiple myeloma patients by giving a myeloma vaccine to patients who are already on lenalidomide (Revlimid) and in a near complete remission.
- Trial name
- NCT01349569
- Testing
- Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein levels are < 5 g/dL following high dose…
- Trial name
- NCT00240162
- Testing
- PTK787/ZK 222584
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma, Fall Risk Factors
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases.
- Conditions
- Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
- Trial name
- Myfall (NCT07044427)
- Testing
- Strength and balance training in combination with a treadmill-based pertubation intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Leukemia, Myeloid, Chronic, Lymphomas
Post Transplant Donor Lymphocyte Infusion
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00167180
- Testing
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Non-Hodgkin, Multiple Myeloma
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00322491
- Testing
- G-CSF Plus Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, Cast Nephropathy
Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy
Hypothesis: Free light chain (FLC) removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma.
- Conditions
- Multiple Myeloma, Cast Nephropathy, Acute Kidney Injury
- Trial name
- KEEPER (NCT02358980)
- Testing
- KIDNEY therapy
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Multiple Myeloma
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in…
- Trial name
- DREAMM 13 (NCT04398680)
- Testing
- Belantamab mafodotin
- Where
- 18 sites in United States, Greece and 1 more
- Sponsor
- GlaxoSmithKline
Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil) schedule in patients with hematological…
- Conditions
- Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy, Leukemia, Acute, Multiple Myeloma
- Trial name
- TrRaMM-TMI (NCT03963024)
- Testing
- Conditioning treatment "Treosulfan-TMI", SCT, GvHD prophylaxis
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS San Raffaele
Multiple Myeloma
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine.
- Trial name
- SEATTLE (NCT05954780)
- Testing
- Selinexor
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- iOMEDICO AG
Vertebral Fracture, Multiple Myeloma
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial.
- Trial name
- NCT04533217
- Testing
- Vertebroplasty
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Spine Centre of Southern Denmark
Multiple Myeloma
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
This is a randomized phase II open label study of daratumumab, weekly low-dose oral cyclophosphamide and dexamethasone with or without pomalidomide in patients with relapsed and refractory multiple myeloma.
- Trial name
- DCDP (NCT03215524)
- Testing
- DCdP, DCd+P
- Where
- 11 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Myeloma Research Group
Multiple Myeloma
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
The purpose of the first phase of the study is to determine whether, and at what dose, depsipeptide, bortezomib and dexamethasone can be safely administered to patients with Multiple Myeloma.
- Trial name
- NCT00431990
- Testing
- depsipeptide, bortezomib, dexamethasone
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy
Pre-malignant States to Hematologic Malignancies in Firefighters
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic…
- Conditions
- Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia
- Trial name
- NCT06870760
- Testing
- Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00743288
- Testing
- Melphalan, Panobinostat
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics